NewsFDAMonday, September 15, 2025 · September 15, 2025
Filspari Approved for IgA Nephropathy
WHY IT MATTERS
First disease-modifying therapy specifically for IgA Nephropathy. Landmark for rare kidney diseases.
The FDA approved Filspari (sparsentan), a dual endothelin and angiotensin receptor antagonist, for IgA nephropathy at risk of disease progression.
Related conditions
Related news
FDA
FDA Approves XTORO
XTORO (FINAFLOXACIN) received FDA approval.…
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.…
FDA
FDA Approves SABRIL
SABRIL (VIGABATRIN) received FDA approval.…
FDA
FDA Approves IOPIDINE
IOPIDINE (APRACLONIDINE HYDROCHLORIDE) received FDA approval.…